Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study


 
 
 Chronic pain is prevalent but difficult to treat in patients undergoing hemodialysis (HD). Effective and safe analgesics are limited in this patient population. Our aim of this feasibility study was to evaluate the safety of sublingual oil based medical cannabis for pain management in patients undergoing HD.
 
 
 
 In a prospective randomized double-blind cross-over design, patients undergoing HD with chronic pain were assigned to one of 3 arms: BOL-DP-o-04-WPE Whole-plant extract (WPE), BOL-DP-o-04 cannabinoid extraction (API) or placebo. WPE and API contained trans-delta9-‏tetrahydrocannabinol (THC) and Cannabidiol (CBD) in 1:6 ratio (1:6, THC: CBD). Patients were treated for 8 weeks, with subsequent 2-weeks wash out, followed by a cross-over to a different arm. The primary endpoint was safety.
 
 
 
 Eighteen patients were recruited and 15 were randomized. Three did not complete drug titration period due to adverse events (AEs) and one patient died during titration due to sepsis (WPE). Of those who completed at least one treatment period, 7 patients were in WPE arm, 5 in API and 9 in placebo. Most common AEs were sleepiness, which improved after dose reduction or patient adaptation. Most AEs were mild to moderate and resolved spontaneously. Serious AEs considered related to study drug included one episode of accidental overdose (WPE) leading to hallucinations. Liver enzymes were stable during cannabis treatment.
 
 
 
 Short term medical cannabis use in patients treated with HD was generally well tolerated. The safety data supports further studies to assess the overall risk-benefit of a treatment paradigm utilizing medical cannabis to control pain in this patient population.
